Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients

Four-drug regimens, such as FIr-B/FOx schedule, can improve efficacy of first-line treatment of metastatic colorectal cancer (MCRC) patients. The present study specifically evaluates feasibility of FIr-B/FOx first-line intensive regimen in fit young-elderly MCRC patients, representing approximately...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruera, Gemma, Cannita, Katia, Giordano, Aldo Victor, Vicentini, Roberto, Ficorella, Corrado, Ricevuto, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3838846/
https://www.ncbi.nlm.nih.gov/pubmed/24307987
http://dx.doi.org/10.1155/2013/143273
_version_ 1782478394267533312
author Bruera, Gemma
Cannita, Katia
Giordano, Aldo Victor
Vicentini, Roberto
Ficorella, Corrado
Ricevuto, Enrico
author_facet Bruera, Gemma
Cannita, Katia
Giordano, Aldo Victor
Vicentini, Roberto
Ficorella, Corrado
Ricevuto, Enrico
author_sort Bruera, Gemma
collection PubMed
description Four-drug regimens, such as FIr-B/FOx schedule, can improve efficacy of first-line treatment of metastatic colorectal cancer (MCRC) patients. The present study specifically evaluates feasibility of FIr-B/FOx first-line intensive regimen in fit young-elderly MCRC patients, representing approximately 40% of overall MCRC patients. Activity, efficacy, and safety were equivalent to overall MCRC patients, not significantly different according to KRAS genotype. Clinical outcome was significantly prolonged in liver-limited compared to other/multiple metastatic disease. Safety evaluation of the individual young-elderly patient showed that limiting toxicity syndromes (LTS) in multiple sites were significantly increased, compared to LTS in single site, with respect to non-elderly patients.
format Online
Article
Text
id pubmed-3838846
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-38388462013-12-04 Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients Bruera, Gemma Cannita, Katia Giordano, Aldo Victor Vicentini, Roberto Ficorella, Corrado Ricevuto, Enrico Biomed Res Int Clinical Study Four-drug regimens, such as FIr-B/FOx schedule, can improve efficacy of first-line treatment of metastatic colorectal cancer (MCRC) patients. The present study specifically evaluates feasibility of FIr-B/FOx first-line intensive regimen in fit young-elderly MCRC patients, representing approximately 40% of overall MCRC patients. Activity, efficacy, and safety were equivalent to overall MCRC patients, not significantly different according to KRAS genotype. Clinical outcome was significantly prolonged in liver-limited compared to other/multiple metastatic disease. Safety evaluation of the individual young-elderly patient showed that limiting toxicity syndromes (LTS) in multiple sites were significantly increased, compared to LTS in single site, with respect to non-elderly patients. Hindawi Publishing Corporation 2013 2013-11-06 /pmc/articles/PMC3838846/ /pubmed/24307987 http://dx.doi.org/10.1155/2013/143273 Text en Copyright © 2013 Gemma Bruera et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Bruera, Gemma
Cannita, Katia
Giordano, Aldo Victor
Vicentini, Roberto
Ficorella, Corrado
Ricevuto, Enrico
Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
title Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
title_full Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
title_fullStr Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
title_full_unstemmed Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
title_short Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
title_sort effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, fir-b/fox, in young-elderly metastatic colorectal cancer patients
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3838846/
https://www.ncbi.nlm.nih.gov/pubmed/24307987
http://dx.doi.org/10.1155/2013/143273
work_keys_str_mv AT brueragemma effectivenessandsafetyofintensivetripletchemotherapyplusbevacizumabfirbfoxinyoungelderlymetastaticcolorectalcancerpatients
AT cannitakatia effectivenessandsafetyofintensivetripletchemotherapyplusbevacizumabfirbfoxinyoungelderlymetastaticcolorectalcancerpatients
AT giordanoaldovictor effectivenessandsafetyofintensivetripletchemotherapyplusbevacizumabfirbfoxinyoungelderlymetastaticcolorectalcancerpatients
AT vicentiniroberto effectivenessandsafetyofintensivetripletchemotherapyplusbevacizumabfirbfoxinyoungelderlymetastaticcolorectalcancerpatients
AT ficorellacorrado effectivenessandsafetyofintensivetripletchemotherapyplusbevacizumabfirbfoxinyoungelderlymetastaticcolorectalcancerpatients
AT ricevutoenrico effectivenessandsafetyofintensivetripletchemotherapyplusbevacizumabfirbfoxinyoungelderlymetastaticcolorectalcancerpatients

Ejemplares similares